The regulatory network of the chemokine CCL5 in colorectal cancer

被引:8
|
作者
Zhang, Xin-Feng [1 ]
Zhang, Xiao-Li [1 ]
Wang, Ya-Jing [2 ]
Fang, Yuan [3 ]
Li, Meng-Li [4 ]
Liu, Xing-Yu [1 ]
Luo, Hua-You [1 ]
Tian, Yan [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 1, Dept Gastrointestinal & Hernia Surg, 296 Xichang Rd, Kunming, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Med Ctr 3, Dept Gen Surg, Beijing, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Organ Transplant Dept, Kunming, Peoples R China
[4] Yunnan Univ, Honghui Hosp, Kunming, Peoples R China
基金
中国国家自然科学基金;
关键词
CCL5; colorectal cancer; immune regulation; immunotherapy; tumor microenvironment; MESENCHYMAL STEM-CELLS; CD8(+) T-CELLS; MAST-CELLS; TUMOR-STROMA; COLON-CANCER; CARCINOMA METASTASIS; DENDRITIC CELLS; PROGRESSION; RECEPTORS; ACTIVATION;
D O I
10.1080/07853890.2023.2205168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The chemokine CCL5 plays a potential role in the occurrence and development of colorectal cancer (CRC). Previous studies have shown that CCL5 directly acts on tumor cells to change tumor metastatic rates. In addition, CCL5 recruits immune cells and immunosuppressive cells into the tumor microenvironment (TME) and reshapes the TME to adapt to tumor growth or increase antitumor immune efficacy, depending on the type of secretory cells releasing CCL5, the cellular function of CCL5 recruitment, and the underlying mechanisms. However, at present, research on the role played by CCL5 in the occurrence and development of CRC is still limited, and whether CCL5 promotes the occurrence and development of CRC and its role remain controversial. This paper discusses the cells recruited by CCL5 in patients with CRC and the specific mechanism of this recruitment, as well as recent clinical studies of CCL5 in patients with CRC. Key Messages CCL5 plays dual roles in colorectal cancer progression. CCL5 remodels the tumor microenvironment to adapt to colorectal cancer tumor growth by recruiting immunosuppressive cells or by direct action. CCL5 inhibits colorectal cancer tumor growth by recruiting immune cells or by direct action.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The Inflammatory Chemokine CCL5 and Cancer Progression
    Aldinucci, Donatella
    Colombatti, Alfonso
    MEDIATORS OF INFLAMMATION, 2014, 2014
  • [2] A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer
    Li, Yuansen
    Lei, Yi
    Sun, Jiaxue
    Zhang, Wanfu
    Li, Xiaogang
    Chen, Sijing
    Kong, Deshenyue
    Chen, Cheng
    Bi, Ke
    Luo, Xiao
    Wang, Hui
    Li, Bo
    Luo, Huayou
    Xu, Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Chemokine complexity - The case for CCL5
    Grayson, Mitchell H.
    Holtzman, Michael J.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2006, 35 (02) : 143 - 146
  • [4] CCR5 and CCL5 in metastatic colorectal cancer
    Schlechter, Benjamin L.
    Stebbing, Justin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [5] Association of chemokine CCL5 and systemic malignancies
    Shailendra Kapoor
    Journal of Human Genetics, 2008, 53 : 377 - 378
  • [6] Angiogenic properties of the chemokine RANTES/CCL5
    Suffee, Nadine
    Richard, Benjamin
    Hlawaty, Hanna
    Oudar, Olivier
    Charnaux, Nathalie
    Sutton, Angela
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2011, 39 : 1649 - 1653
  • [7] Association of chemokine CCL5 and systemic malignancies
    Kapoor, Shailendra
    JOURNAL OF HUMAN GENETICS, 2008, 53 (05) : 377 - 378
  • [8] Chemokine CCL5 immune subtypes of human liver cancer with prognostic significance
    Xia, Yin
    Zhou, Linlin
    Yang, Hung-Chih
    Yu, Chen-Wei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [9] Gene polymorphisms of CCL3, CCL4, CCL5, and CCR5 network in metastatic colorectal cancer patients treated with regorafenib
    Suenaga, Mitsukuni
    Zhang, Wu
    Mashima, Tetsuo
    Schirripa, Marta
    Cao, Shu
    Okazaki, Satoshi
    Berger, Martin D.
    Miyamoto, Yuji
    Barzi, Afsaneh
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] CCL5 as an adjuvant for cancer immunotherapy
    Lapteva, Natalia
    Huang, Xue F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (05) : 725 - 733